Cargando…
Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
Therapeutic options to control respiratory syncytial virus (RSV) are limited, thus development of new therapeutics is high priority. Previous studies with a monoclonal antibody (mAb) reactive to an epitope proximal to the central conserved region (CCR) of RSV G protein (mAb 131-2G) showed therapeuti...
Autores principales: | Caidi, Hayat, Harcourt, Jennifer L., Tripp, Ralph A., Anderson, Larry J., Haynes, Lia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531420/ https://www.ncbi.nlm.nih.gov/pubmed/23300550 http://dx.doi.org/10.1371/journal.pone.0051485 |
Ejemplares similares
-
Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice
por: Rey, Gertrud U., et al.
Publicado: (2013) -
The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection
por: Bakre, Abhijeet A., et al.
Publicado: (2017) -
Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020) -
Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023) -
Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection()
por: Harcourt, Jennifer L., et al.
Publicado: (2011)